NCT05074303 (M-Unity) is a Phase 2 clinical trial of Influenza Vaccine in Healthy Aging, sponsored by University of Florida.

Who is sponsoring NCT05074303?

NCT05074303 is sponsored by University of Florida.

What drugs are being tested in NCT05074303?

Interventions in NCT05074303: Influenza Vaccine, Beta-glucan, Placebo.

What condition does NCT05074303 study?

NCT05074303 studies Healthy Aging.

Is NCT05074303 still recruiting?

NCT05074303 is currently completed. Last updated 6 November 2025.

Are results published for NCT05074303?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-11-06 · How we verify

NCT05074303: M-Unity

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Beta-glucan and Immune Response to Influenza Vaccine

Completed Phase 2 Results posted Last updated 6 November 2025

What this trial tests

Phase 2 trial testing Influenza Vaccine in Healthy Aging in 78 participants. Completed in 28 August 2024.

Timeline

18 July 2022

Primary endpoint
1 March 2024

28 August 2024

Quick facts

Lead sponsor	University of Florida
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	other
Enrollment	78
Start date	18 July 2022
Primary completion	1 March 2024
Estimated completion	28 August 2024
Sites	1 location across United States

Drugs / interventions tested

Influenza Vaccine — full drug profile →
Beta-glucan — full drug profile →
Placebo

Conditions studied

Healthy Aging — all drugs for Healthy Aging →

Sponsor

University of Florida

Who can join

Adults 50 to 100, any sex, with Healthy Aging. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Antibody Titer Primary · 42 days (mean of Day -14 and 0 compared to Day 28)

Change in influenza-specific antibody influenza A titer to the influenza vaccine after beta-glucan supplementation. Titer from 0 to 1024; higher titer indicates stronger immune response.

Baseline (Mean of Day -14 and Day 0)

Group	Value	95% CI
Beta-glucan	127	± 105
Placebo	143	± 172

Intervention (Day 28)

Group	Value	95% CI
Beta-glucan	241	± 272
Placebo	160	± 165

Inflammatory Cytokine Profile Secondary · 28 days (Day 0, Day 1, and Day 28)

Change in IFN-γ

Day 0

Group	Value	95% CI
Beta-glucan	2.3	± 0.1
Placebo	2.4	± 0.4

Day 1

Group	Value	95% CI
Beta-glucan	8.2	± 1.7
Placebo	8.3	± 2.9

Day 28

Group	Value	95% CI
Beta-glucan	3.3	± 0.5
Placebo	2.3	± 0.4

Incidence of Influenza and Covid-19 Secondary · 28 days

Self-reported incidence of influenza and Covid-19

Group	Value	95% CI
Beta-glucan	0
Placebo	0

Fever Secondary · 28 days

Number of subjects with self-reported fever

Group	Value	95% CI
Beta-glucan	1
Placebo	1

Cold and Flu Symptoms Secondary · 28 days

Score on the Modified Jackson Criteria rating scale from 0 (no symptoms) to 3 (severe symptoms).

Group	Value	95% CI
Beta-glucan	0.92	± 0.07
Placebo	0.70	± 0.06

Sponsor's own description

This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Yeast Beta-Glucan Enhances Antibody Response Following Influenza Vaccination - A Double-Blind, Randomized, Placebo-Controlled Pilot Trial.
Moreno ML, Nieves CJ, Hebert K, Vivas CA, et al · · 2025 · cited 2× · PMID 40746014 · DOI 10.1080/19390211.2025.2539876

Verify or expand the search:

Other trials of Influenza Vaccine

Trials testing the same drug.

NCT06864143 — A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in A · Phase 2 · completed
NCT06097273 — A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age · Phase 3 · completed
NCT05519839 — A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine · Phase 2 · completed
NCT05294588 — Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae · Phase 2 · completed
NCT05091307 — A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults · Phase 3 · completed

Other recruiting trials for Healthy Aging

Currently open trials in the same condition.

NCT07515495 — Effectiveness of Intensive Tutoring vs. Flexible Self-Learning on Digital Health Literacy and Self-Efficacy for "My Heal · NA · recruiting
NCT07231783 — The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults · NA · recruiting
NCT07308353 — Comparative Effects Of Exergaming And Otago Exercise On Anticipatory Postural Control And Sensory Integration In Older A · NA · active not recruiting
NCT07207044 — FAXAGE: Fasting And Exercise To Slow Aging In Humans · NA · recruiting
NCT07151365 — Plant-based Diets and Healthy Aging · recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05074303 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 6 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05074303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing